The BIOSECURE Act was signed into US law on 18 December 2025 as part of the National Defense Authorization Act for fiscal year 2026. It restricts US government contracting with organisations that use designated foreign biotechnology companies of concern, with the list of designated companies due by 18 December 2026 and prohibitions phasing in over the following years.
The details are still moving. In August 2026 a US court enjoined the Department of Defense listing of WuXi AppTec, one of the largest contract research, development and manufacturing organisations. But the direction of travel is clear, and companies are acting now: a manufacturing partner chosen in 2026 may still be supplying a product in the 2030s.
Why this matters for hiring
Dependence on overseas partners is widespread. A Biotechnology Innovation Organization survey found that 79% of responding biopharma companies had at least one contract or product agreement with a China-based or China-owned CDMO or CMO. Moving even part of that work, combined with tariff-driven reshoring, creates projects that need specific people:
- Tech transfer and MSAT specialists to move processes between sites and partners.
- Supplier quality engineers and auditors to qualify new manufacturers.
- CMC and regulatory CMC professionals to manage the filings that follow a change of site.
- External manufacturing and supply chain managers to run a broader partner network.
Who is hiring
Demand is landing on both sides: sponsors building internal teams to manage new partners, and Western CDMOs expanding capacity to take on the work. Both are recruiting from the same small pool of people who have done a transfer before.
Sources: Greenberg Traurig, BIOSECURE Act update. KBI Biopharma, BIOSECURE, tariffs and the new CDMO reality. South China Morning Post, US reshoring and contract drug makers.